| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Piribedil D8 is a labeled form of piribedil, which targets dopamine receptors as a dopamine agonist. Piribedil acts as a dopamine agonist, stimulating dopamine receptors in the brain and helping to alleviate the motor symptoms associated with Parkinson's disease, such as tremors, rigidity, and bradykinesia. Piribedil also displays alpha2-adrenergic antagonist properties. The compound has been shown to counteract age-related memory impairment by improving memory and attention as well as increasing the velocity of psychomotor reactions and lability of nervous processes. The deuterium-labeled form has the same pharmacological properties as the unlabeled compound but is used as an analytical standard.
|
|---|---|
| ln Vitro |
Piribedil D8 itself is not evaluated for pharmacological activity, as it is used as an analytical standard. Piribedil, the unlabeled compound, is an antiparkinsonian agent that acts as a dopamine agonist. It also displays alpha2-adrenergic antagonist properties. The deuterium-labeled form is used as an internal standard for the quantification of piribedil in biological samples by mass spectrometry. Its activity is not characterized in terms of pharmacological effects but rather in terms of analytical properties such as mass spectrometric response and chromatographic behavior. The compound serves as a stable isotope-labeled internal standard for analytical method development.
|
| ln Vivo |
In vivo activity of Piribedil D8 is not applicable, as the compound is used as an analytical standard rather than as a therapeutic agent. Piribedil, the unlabeled compound, is used clinically for the treatment of Parkinson's disease and other related movement disorders. It is an antiparkinsonian agent that acts as a dopamine agonist. The deuterium-labeled form is not administered therapeutically and is not intended for in vivo studies. Its primary use is as an internal standard for mass spectrometry-based quantification of piribedil in biological samples from clinical or preclinical studies.
|
| Enzyme Assay |
In vitro assays for Piribedil D8 are primarily analytical rather than pharmacological. The compound is used as an internal standard for the quantification of piribedil in biological samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The deuterium-labeled compound has the same chemical properties as the unlabeled compound but a different mass, allowing it to be distinguished from the endogenous analyte. Analytical methods using Piribedil D8 involve extraction of piribedil from biological samples (plasma, urine), chromatographic separation, and mass spectrometric detection. The compound's purity and stability are characterized to ensure its suitability as an analytical standard.
|
| Cell Assay |
In vitro cellular assays are not applicable for Piribedil D8, as the compound is used as an analytical standard rather than for biological activity studies. The compound is not evaluated in cell-based assays for pharmacological activity. Its primary use is in analytical chemistry for the quantification of piribedil in biological samples. If cellular assays were to be performed, appropriate cell lines expressing dopamine receptors could be used to assess the biological activity of the unlabeled compound. However, such studies are not typically conducted for deuterium-labeled analytical standards.
|
| Animal Protocol |
In vivo animal studies are not applicable for Piribedil D8, as the compound is used as an analytical standard rather than as a therapeutic agent. The deuterium-labeled compound is not administered to animals for efficacy or safety studies. Its primary use is in analytical chemistry for the quantification of piribedil in biological samples from clinical or preclinical studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Piribedil D8 are not relevant, as the compound is used as an analytical standard rather than as a therapeutic agent. The compound has a molecular formula of C16H10D8N4O2 and a molecular weight of 306.39 g/mol. It is also known as Trivastal-d8 and Trivastan-d8. The compound is used as an internal standard for LC-MS/MS analysis of piribedil. Its stability and purity are characterized to ensure its suitability for analytical applications. Comprehensive pharmacokinetic parameters are not relevant for an analytical standard.
|
| Toxicity/Toxicokinetics |
Piribedil D8 is intended for laboratory research use only and has not undergone toxicology testing for therapeutic applications. As a deuterium-labeled analytical standard, the compound is used in small quantities for analytical purposes. Standard handling precautions for chemical research compounds should be followed. Comprehensive toxicological characterization has not been reported, as the compound is not intended for human use. Piribedil D8 is strictly intended for research purposes as an analytical standard.
|
| Additional Infomation |
Piribedil D8 (Piribedil-d8, ET-495 D8) is the deuterium-labeled form of piribedil, an antiparkinsonian agent and dopamine agonist. Piribedil is a piperazine derivative that acts as an alpha2-adrenergic antagonist and can be used to improve cognition. Piribedil D8 has a molecular formula of C16H10D8N4O2 and a molecular weight of 306.39 g/mol. The compound is used as an internal standard for the quantification of piribedil in biological samples by mass spectrometry. Piribedil D8 has not entered clinical trials and is available for research purposes only.
|
| Molecular Formula |
C16H10D8N4O2
|
|---|---|
| Molecular Weight |
306.389
|
| Exact Mass |
306.193
|
| CAS # |
1398044-45-5
|
| Related CAS # |
Piribedil;3605-01-4;Piribedil hydrochloride;78213-63-5
|
| PubChem CID |
12804974
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
469.4±55.0 °C at 760 mmHg
|
| Flash Point |
237.7±31.5 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.632
|
| LogP |
2.36
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
356
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C1(C(N(C(C(N1CC2=CC3=C(C=C2)OCO3)([2H])[2H])([2H])[2H])C4=NC=CC=N4)([2H])[2H])[2H]
|
| InChi Key |
OQDPVLVUJFGPGQ-COMRDEPKSA-N
|
| InChi Code |
InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2/i6D2,7D2,8D2,9D2
|
| Chemical Name |
1-(1,3-benzodioxol-5-ylmethyl)-2,2,3,3,5,5,6,6-octadeuterio-4-pyrimidin-2-ylpiperazine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2638 mL | 16.3191 mL | 32.6381 mL | |
| 5 mM | 0.6528 mL | 3.2638 mL | 6.5276 mL | |
| 10 mM | 0.3264 mL | 1.6319 mL | 3.2638 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
